Tauseef Butt

Company: Progenra

Job title: President & Chief Executive Officer

Seminars:

Roundtable Learning Session: Evaluating a Combination of Therapeutic Approaches with TPD to Treat Anti-Microbial Resistance & Improve Patient Outcomes 2:00 pm

Understanding the different combination approaches currently available for resistant diseases. Learning how combination approaches can combat challenges faced in mono-therapeutic approaches. Theorizing how the field can utilize combination approaches in overcoming resistance.Read more

day: Pre-Conference Day

Targeted Degradation of SARS-CoV-2 Proteases for Antiviral Therapy 10:30 am

Targeted protein degradation of viral proteins has distinct advantages over the traditional drugs, chief being lack resistance. SARS-CoV2 genome encodes two proteases, 3 CLpro (NSP3) and PLpro (NSP5), both are essential genes for the virus replication. Progenra has developed PROTACs against SARS-CoV2 PLpro. The PLpro PROTACs are potent degraders of the protein and demonstrate superior…Read more

day: Pre-Conference Day